Ozempic Approved to Treat Chronic Kidney Disease in US
January 29, 2025
22,156
144
19
0.74%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Bloomberg News Episodes Around January 29, 2025
See what was published immediately before and after this episode.
0:19Now PlayingOzempic Approved to Treat Chronic Kidney Disease in US
YouTube Description
as posted by the channelNovo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 diabetes, further expanding the popular drug’s use. #ozempic #weightloss #health #fda
Chronic kidney disease is a common complication of type 2 diabetes and affects more than 35.5 million US adults, according to the Centers for Disease Control and Prevention. The approval from the Food and Drug Administration is the latest example of how Ozempic and other drugs like it, called GLP-1s, are being used to treat diabetes-related conditions, such as heart disease.
Expanding the use of Novo’s semaglutide — branded as Ozempic for diabetes and Wegovy for weight loss — is a crucial part of the Danish drugmaker’s efforts to boost access and sales.
Shares of Novo opened up about 1% in early trading Wednesday. The stock is down 18% in the past 12 months through Tuesday’s close.
--------
Subscribe to our YouTube channel
Subscribe to Bloomberg Originals
Bloomberg Quicktake brings you global social video spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.
Connect with us on…
Breaking News on YouTube
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.